1. Market Research
  2. > IT Services
  3. > Hosting Market Trends
  4. > Recurrent Glioblastoma Multiforme (GBM)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017


DelveInsight’s Report, “Recurrent Glioblastoma Multiforme (GBM)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Recurrent Glioblastoma Multiforme (GBM) Report is to understand the market and pipeline status of the drugs around the Recurrent Glioblastoma Multiforme (GBM) to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline startegies. The DelveInsight’s Report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Recurrent Glioblastoma Multiforme (GBM). While the leading brands, companies and chemicals are considered thoroughly, DelveInsight’s report also provides details on the Global API Manufacturers across the globe covering Drug Master Filings of US, Europe and API Manufacturers in Asia specifically China and India.

Please note:This report requires certain updates. We have all the information available but require 48-72 Hours to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE:
- A snapshot of the global Market and Phase III therapeutics scenario for Recurrent Glioblastoma Multiforme (GBM).
- A review of the marketed products under prescription for Recurrent Glioblastoma Multiforme (GBM), regulatory information and marketing status.
- Coverage of global patent coverage and detailed commentaries on the US patent challenges.
- Graphical representation of investigational products for patent expiry and market exclusivities across the globe.
- Product profiles for marketed products for Recurrent Glioblastoma Multiforme (GBM) with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.
- Coverage of API Manufacturers for Recurrent Glioblastoma Multiforme (GBM) drugs in the United States, Europe and Asian Regions with location details.
- Coverage of Regulatory filings in theUS, Europe, and Asia specifically India and China for Recurrent Glioblastoma Multiforme (GBM) drugs.
- Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Recurrent Glioblastoma Multiforme (GBM) drugs.
- Coverage of Recurrent Glioblastoma Multiforme (GBM) Phase III pipeline products featuring sections on product description, mechanism of action, Chemical details and research & development progress.
- Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs.
- Key discontinued Marketed products.
- Global Sales Figure to 2018.

Reasons to buy:
- Evaluate the marketing status and exclusivity details of Recurrent Glioblastoma Multiforme (GBM) key products to exploit opportunities for generic drug development opportunities.
- Identify and understand important and diverse types of therapeutics under Phase III development for Recurrent Glioblastoma Multiforme (GBM).
- Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Recurrent Glioblastoma Multiforme (GBM).
- API intelligence over marketed drugs forRecurrent Glioblastoma Multiforme (GBM)and gaining primary intelligence over active ingredients manufacturers across the globe.
- API intelligence over leading Phase III Pipeline drugs.
- Develop and designstrategies by identifying the API manufacturers for Phase III Pipeline products to enhance and expand business potential and scope.
- Understanding the scope of the Phase III Drugs with nil regulatory filings.
- Understanding the chemical route of synthesis of approved drugs for Recurrent Glioblastoma Multiforme (GBM).
- Uncovering opportunities in the rapidly growing US market.

Table Of Contents

Recurrent Glioblastoma Multiforme (GBM)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
Illustrative
1. Indication Overview
2. Market Drugs Landscape
2.1 Marketed Drugs
2.2 Marketed Details of Drugs by Application Type
2.3 Marketed Details of Drugs (NDA) by Marketing Status
2.4 Marketed Details of Drugs by Patent Expiration Timeline
3. Global API Manufacturers Assessment
3.1 API Manufacturers by United States Drug Master File (US DMF) Status
3.2 API Manufacturers by US DMF Status (Drug Specific)
3.3 API Manufacturers in Europe by Country
3.4 API Manufacturers in India by State
3.5 API Manufacturers in China by Province
3.6 Marketed Details of Approved Drugs by Geography
4. Phase III Drugs Landscape
4.1 Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs
4.2 API Manufacturers by US DMF Status (Drug Specific)
5. Drugs Market Data and Forecasted Sales Figure-2018
6. Marketed Drugs for Recurrent Glioblastoma Multiforme (GBM)
6.1 Drug Name
6.1.1 Drug Description
6.1.2 Global Active Pharmaceutical Manufacturers for Drug
6.1.3 Approval Status of Drug
6.1.4 Patent and Exclusivity Details for Drug
6.1.5 Company Profile and Financials
7. Phase III Drugs for Recurrent Glioblastoma Multiforme (GBM)
7.1 Drug Name
7.1.1 Drug Description
7.1.2 United States Drug Master File (DMF)
8. Discontinued Drugs for Recurrent Glioblastoma Multiforme (GBM)
9. Appendix
10. Methodology
11. Consulting Services
12. Contact Us
13. Disclaimer


List of Tables

- Recurrent Glioblastoma Multiforme (GBM) Therapeutic Market, US, Marketed Drugs by Application Type, 2017
- Recurrent Glioblastoma Multiforme (GBM) Therapeutic Market, US, Marketed Drugs by Marketing Status, 2017
- Recurrent Glioblastoma Multiforme (GBM) Therapeutic Market, US, (Year), 2017
- Recurrent Glioblastoma Multiforme (GBM) Marketed Drugs, API Manufacturers by US DMF Status, 2017
- Recurrent Glioblastoma Multiforme (GBM) Marketed Drugs, US DMF Status Drug Specific (Number), 2017
- Recurrent Glioblastoma Multiforme (GBM) Drugs, API Manufacturers, Europe by Country, 2017
- Recurrent Glioblastoma Multiforme (GBM) Drugs, API Manufacturers, India by State, 2017
- Recurrent Glioblastoma Multiforme (GBM) Drugs, API Manufacturers, China by Province, 2017
- Recurrent Glioblastoma Multiforme (GBM) Drugs, API Manufacturers by Geography 2017
- Recurrent Glioblastoma Multiforme (GBM) Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2017
- Recurrent Glioblastoma Multiforme (GBM) Therapeutic Market, Global Sales-2018 (in million USD)
- API Manufacturers for Drug, 2017
- Phase III Drugs for Recurrent Glioblastoma Multiforme (GBM), 2017
- Discontinued Drugs for Recurrent Glioblastoma Multiforme (GBM), 2017


List of Figures

- Recurrent Glioblastoma Multiforme (GBM) Therapeutic Market, US, Marketed Drugs by Application Type (%), 2017
- Recurrent Glioblastoma Multiforme (GBM) Therapeutic Market, US, Marketed Drugs by Marketing Status (%), 2017
- Recurrent Glioblastoma Multiforme (GBM) Therapeutic Market, US, (Year), 2017
- Recurrent Glioblastoma Multiforme (GBM) Marketed Drugs, API Manufacturers by US DMF Status (%), 2017
- Recurrent Glioblastoma Multiforme (GBM) Marketed Drugs, US DMF Status Drug Specific (Number), 2017
- Recurrent Glioblastoma Multiforme (GBM) Drugs, API Manufacturers, Europe by Country, 2017
- Recurrent Glioblastoma Multiforme (GBM) Drugs, API Manufacturers, India by State, 2017
- Recurrent Glioblastoma Multiforme (GBM) Drugs, API Manufacturers, China by Province, 2017
- Recurrent Glioblastoma Multiforme (GBM) Drugs, API Manufacturers by Geography 2017
- Recurrent Glioblastoma Multiforme (GBM) Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2017
- Recurrent Glioblastoma Multiforme (GBM) Therapeutic Market, Global Sales 2018 (in million USD)
- Drug, Patent/Exclusivity Expiry (Year), 2017

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Data Center as a Bottleneck: Market Strategies, Analysis and Opportunities

Data Center as a Bottleneck: Market Strategies, Analysis and Opportunities

  • $ 19000
  • Industry report
  • January 2017
  • by WinterGreen Research

This 2017 module has 138 pages and 67 tables and figures Worldwide hyperscale data center markets implement cloud computing with shared resource and the aim, more or less achieved of providing foolproof ...

Network management and orchestration systems: worldwide market shares 2015

Network management and orchestration systems: worldwide market shares 2015

  • $ 7999
  • Industry report
  • November 2016
  • by Analysys Mason

"Next-generation virtual network management and orchestration spending increased to USD530 million in 2015, reflecting significantly increased operator investment in virtual networks." This report assesses ...

Field Service Management Market by Solution, Service, Deployment Type, User Type, Industry Vertical, and Region - Global Forecast to 2021

Field Service Management Market by Solution, Service, Deployment Type, User Type, Industry Vertical, and Region - Global Forecast to 2021

  • $ 7150
  • Industry report
  • March 2017
  • by MarketsandMarkets

“The growing need for a highly scalable centralized system for the management of field services is expected to drive the Field Service Management (FSM) market” The FSM market size is expected to grow ...

Top 10 Security Technologies

February 2017 $ 5650

Top 10 Cloud Technology Market

February 2017 $ 5650

ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.